It is expected to change the treatment model of first-line lymphoma Roche ADC combination reduces the risk of disease progression by 27%

On December 14, 2021, Genentech, a Roche subsidiary, announced that the "first-in-class" CD79b-targeted antibody-conjugated drug (ADC) Polivy (polatuzumab vedotin) will be linked to a treatment program called R-CHP It has been used in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL) in Phase 3 clinical trials with positive results

DLBCL is the most common type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of NHL

The CD79b protein is specifically expressed in most B cells, making it a promising target for the development of new therapies

This phase 3 clinical trial evaluated Polivy+rituximab+cyclophosphamide+doxorubicin+prednisone in 879 previously untreated DLBCL patients, compared with rituximab Efficacy, safety and pharmacokinetics of standard treatment of monoclonal antibody + cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP)

The efficacy and safety data of the trial showed that at a median follow-up of 28.

▲Polivy+R-CHP significantly improves the progression-free survival of patients (picture source: reference [2])

Reference materials:

[1] Roche's Polivy Combination Reduced The Risk Of Disease Worsening Or Death By 27% In People With Previously Untreated Aggressive Form Of Lymphoma.

[2] Tilly et al.

(The original text has been deleted)